Results 11 to 20 of about 4,505 (178)

Saxagliptin for type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2010
Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients ...
Chacra
doaj   +7 more sources

Saxagliptin [PDF]

pharma-kritik, 2010
Ein weiteres «Gliptin-Antidabetikum», das den Abbau der Inkretine hemmt. Gegenüber Sitagliptin und Vildagliptin sind keine grossen Unterschiede zu erkennen. 
Sum, Lam, Maha, Saad
openaire   +3 more sources

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

BMC Pharmacology and Toxicology, 2015
Background The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were ...
M Elle Saine, Dean M Carbonari, Craig W Newcomb, Melissa S Nezamzadeh, Kevin Haynes, Jason A Roy, Serena Cardillo, Sean Hennessy, Crystal N Holick, Daina B Esposito, Arlene M Gallagher, Harshvinder Bhullar, Brian L Strom, Vincent Lo Re   +13 more
doaj   +1 more source

Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats

Journal of Pharmacological Sciences, 2016
Saxagliptin, a potent and selective DPP-4 inhibitor, is characterized by its slow dissociation from DPP-4 and its long half-life and is expected to have a potent tissue membrane-bound DPP-4-inhibitory effect in various tissues.
Junichi Ikeda, Naoya Kimoto, Tetsuya Kitayama, Shunji Kunori   +3 more
doaj   +1 more source

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin

Cardiovascular Diabetology, 2017
Background In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial in patients with type 2 diabetes mellitus (T2D) at high risk of cardiovascular (CV) disease, saxagliptin did not increase the risk for
Pia S. Pollack, Kristina D. Chadwick, David M. Smith, Martin Billger, Boaz Hirshberg, Nayyar Iqbal, David W. Boulton   +6 more
doaj   +1 more source

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo

Journal of Pharmacological Sciences, 2017
Saxagliptin, a potent and selective DPP-4 inhibitor, exhibits a slow dissociation from DPP-4. We investigated the sustained effects of saxagliptin on renal DPP-4 activity in a washout study using renal tubular (HK-2) cells, and in a pharmacodynamic study
Masako Uchii, Mariko Sakai, Yuhei Hotta, Satoshi Saeki, Naoya Kimoto, Akinori Hamaguchi, Tetsuya Kitayama, Shunji Kunori   +7 more
doaj   +1 more source

Evaluation of the Drug-Induced Liver Injury Potential of Saxagliptin through Reactive Metabolite Identification in Rats

Pharmaceutics
A liver injury was recently reported for saxagliptin, which is a dipeptidyl peptidase-4 (DPP-4) inhibitor. However, the underlying mechanisms of saxagliptin-induced liver injury remain unknown.
Ki-Young Kim, Yeo-Jin Jeong, So-Young Park, Eun-Ji Park, Ji-Hyeon Jeon, Im-Sook Song, Kwang-Hyeon Liu   +6 more
doaj   +1 more source

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

Cardiovascular Diabetology, 2012
Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular (CV) disease; however, conclusive evidence that glycemic control leads to improved cardiovascular outcomes is lacking.
Cobble Michael E, Frederich Robert
doaj   +1 more source

Beyond Simple Mimicry: Next‐Generation Geometric Architectures and Future Paradigms in Small‐Molecule and Macrocyclic Peptidomimetics

Angewandte Chemie International Edition, EarlyView.
Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee, Sumin Son, Jeong Yeon Yoo, Ji Hyae Lee, Meehyun Chun, Seung Bum Park   +5 more
wiley   +1 more source

Efficacy of Saxagliptin versus Mitiglinid in patients with type 2 diabetes and end-stage renal disease

Renal Replacement Therapy, 2017
Background There are very few oral antidiabetic drugs recommended for patients on dialysis. Saxagliptin is known for its potent effect and long duration of action.
Yukinao Sakai, Saori Sakai, Koji Mugishima, Anna Katayama, Yuichiro Sumi, Yusuke Otsuka, Tomoyuki Otsuka, Shuichi Tsuruoka   +7 more
doaj   +1 more source